Mizuho Securities Starts Allergen (AGN) at Buy

Mizuho Securities initiates coverage on Allergen (NYSE: AGN) with a Buy rating and a price target of $337.00.

Analyst Irina Koffler commented, "Allergan is a high quality, proactivelymanaged, company with attractive, durable assets and a valuable pipeline. It's pending sale of the Actavis generics unit should infuse approximately $40 billion into its balance sheet, setting up a 'high-class' problem relative to its more cash-strapped peers."

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $268.99 yesterday.

You May Also Be Interested In

• Jefferies Downgrades Calix (CALX) to Hold
• Helen of Troy (HELE) PT Raised to $151 at DA Davidson
• Meta Platforms Inc. (META) PT Lowered to $480 at JPMorgan, 'Bigger AI Ambitions Drive Increasing Infrastructure Investments'